Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727034 | 0.84 | HRH3 (0.44) | SMN1; SMN2HRH3KMT2AALDH1A1MEN1 | |
| SCHEMBL17177230 | 0.83 | HRH3 (0.46) | SMN1; SMN2HRH3HTTALOX15KMT2A | |
| SCHEMBL10884745 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2HRH3CXCR4HTTBAZ2A | |
| SCHEMBL2929353 | 0.80 | KDM4E (0.45) | SMN1; SMN2HRH3HTTKMT2AALDH1A1 | |
| SCHEMBL12126285 | 0.80 | HRH3 (0.51) | SMN1; SMN2HRH3CXCR4HTTBAZ2A | |
| SCHEMBL27870171 | 0.80 | ALDH1A1 (0.45) | HRH3CXCR4BAZ2AALOX15KMT2A | |
| SCHEMBL10426668 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2HRH3CXCR4HTTBAZ2A | |
| Hydrochloric Acid SCHEMBL906980 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2HRH3CXCR4HTTBAZ2A | |
| SCHEMBL30911533 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2HRH3CXCR4HTTBAZ2A | |
| SCHEMBL17331423 | 0.76 | HRH3 (0.48) | SMN1; SMN2HRH3CXCR4HTTBAZ2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| EP-3157920-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2017-04-26 | — | — | EP | disclosed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| WO-2015193263-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| EP-2417127-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| CN-101247804-A | chemical compound | SMITHKLINE BEECHAM CORP (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | SMN1; SMN2 4366/4885HRH3 568/4885CXCR4 1105/4885 |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | SMN1; SMN2 4639/4885HRH3 3367/4885CXCR4 2715/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | SMN1; SMN2 4502/4885HRH3 3894/4885CXCR4 3110/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | SMN1; SMN2 4639/4885HRH3 3367/4885CXCR4 2715/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | SMN1; SMN2 4639/4885HRH3 3367/4885CXCR4 2715/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | SMN1; SMN2 4366/4885HRH3 568/4885CXCR4 1105/4885 |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIP4K2B, PIP5K1B, PIP4K2A | SMN1; SMN2 4653/4885HRH3 2093/4885CXCR4 2803/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | SMN1; SMN2 4639/4885HRH3 3367/4885CXCR4 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.